Ivonescimab in advanced squamous non-small-cell lung cancer: can we raise the survival bar? Tina Casconea,† Send email to tcascone@mdanderson.org ∙ Giannis Mountzios

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01026-3/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco26&_hsenc=p2ANqtz-8RFIQw3ag3roNL_bE93yyUHT-zyt7zwvt7aCVfvNqOpOO55_sa8vzJwB-hTw-GATl_tlFnqQicBfJciUqeRqi5V6lWWQ&_hsmi=421795296&utm_content=421795296&utm_source=hs_email

Redefining first-line standards with new partners Stephanie P L Sawa ∙ Jordi Remon

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01038-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco26&_hsenc=p2ANqtz--3M8l7S7TAw5QgszaAGVnu4WjCPFpItZNeuNrrB7J4I9sQaGw86snt6g7Dzrjb7TFZse86jBoJxSIlYltvHtPUs8HEUQ&_hsmi=421795296&utm_content=421795296&utm_source=hs_email

Moving beyond R-CHOP in large B-cell lymphoma Marcel Nijland

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01069-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco26&_hsenc=p2ANqtz-86HRQKu06RXqZFVbhzqVmzIRM7hzdr4ZKtSGAPOEE0bhI8YEk3BYboN9thh-88jdnRFgeKJmXmLHKbQC6wO6LJgsfgFg&_hsmi=421795296&utm_content=421795296&utm_source=hs_email

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study Prof Lin Shen, MDa,* Send email to shenlin@bmju.edu.cn ∙ Prof Xiaotian Zhang, MDa,b,* ∙ Ke Ji, MDc,* ∙ Prof Linzhi Lu, MDd,* ∙ Prof Quan Wang, MDe,* ∙ Prof Quanlin Guan, MDf ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00974-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco26&_hsenc=p2ANqtz-85HEhQUOIH_jiIF3OUcRSKQKZPzARwhO8ugL2s-CVCqeNok5I2LzAiF1xp7wBq4W4Cy40pjUB972ip0AQnPGRfYx_Oow&_hsmi=421795296&utm_content=421795296&utm_source=hs_email

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China Prof Shun Lu, MDa,† Send email to shunlu@sjtu.edu.cn ∙ Prof Baogang Liu, MDb,† ∙ Prof Yongzhong Luo, MDc,† ∙ Prof Longhua Sun, MDd,† ∙ Prof Lin Wu, MDc,† ∙ Prof Zhengxiang Han, MDe ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00966-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco26&_hsenc=p2ANqtz-9g8nFSiWYmWS6GIcdQy-ne0gMn_25Nu_7PlYMtrZu6DiaBjpMr0LL1qgQIdA_Sxs8Z354DNyG5NEYSCzwm0mgPWYAkEA&_hsmi=421795296&utm_content=421795296&utm_source=hs_email

Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial

Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial Prof Anwen Xiong, MDa,* ∙ Prof Wenxiu Yao, MDb,* ∙ Prof Wei Zheng, MDc,* ∙ Yan Yu* ∙ Peng Chen, MDe,* ∙ Prof Hua Zhong, MDf,* ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00968-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco26&_hsenc=p2ANqtz-_1h5vEtu4pLpKadWtqaVc7nT_ajP697uA04ByYzhu8Wy_q326x-Y1guSBgDH-se3sYUyDsd_BeC4t6EvdDIuuNNEEbdw&_hsmi=421795296&utm_content=421795296&utm_source=hs_email

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial Prof Georg Lenz, MDa Send email to georg.lenz@ukmuenster.de ∙ Prof Marek Trněný, MDb ∙ John M Burke, MDc ∙ Prof Grzegorz S Nowakowski, MDd ∙ Prof Christopher P Fox, MDe ∙ Annalisa Chiappella, MDf ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00866-4/fulltext?dgcid=hubspot_email_conferencealerts_asco26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8du9f3KbFXeViPaNdIfUL7SdCGXnyCiHg-pSz23BePt35DKMTLw_zFZzAh8ID7-ybLQiWFryhUwQI5UNoVCqoXW3D49Q&_hsmi=421795296&utm_content=421795296&utm_source=hs_email